Patients with moderately severe to severe Alzheimer’s disease are often prescribed a combination of cholinesterase inhibitors and mermatine. From the clinical studies available to date, no significant advantage can be discerned over administration of just one of the two medicines. Therefore, combined therapy is not recommended by the SMB for these patients, which is in line with the current reimbursement practice of the health insurers.